Sunesis Pharmaceuticals

US: SNSS

$86.6m market cap

$0.78 last close

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Investment summary

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead programme is vecabrutinib, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers were recently presented and indicated an attractive PK/PD profile with twice-a-day dosing. The programme is in a dose-escalation Phase Ib/II trial. It has also developed TAK-580 with partner Takeda, and the preclinical PDK1 inhibitor SNS-510.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.7 (34.4) (35.5) (144.63) N/A N/A
2018A 0.2 (25.7) (26.6) (74.80) N/A N/A
2019E 0.0 (28.1) (28.6) (38.67) N/A N/A
2020E 0.0 (29.3) (33.2) (42.91) N/A N/A
Last updated on 15/08/2019
Industry outlook

Sunesis is an oncology company with an early-stage asset with a validated target for the treatment of B-cell malignancies.

Last updated on 15/08/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 0.2
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (9.6) (35.7) (62.8)
Relative* (4.3) (35.7) (63.2)
52-week high/low US$2.2/US$0.2
*% relative to local index
Key management
William Quinn Chief Financial Officer and Senior Vice Presi

Content on Sunesis Pharmaceuticals